作者
Stefan Rutkowski, Udo Bode, Frank Deinlein, Holger Ottensmeier, Monika Warmuth-Metz, Niels Soerensen, Norbert Graf, Angela Emser, Torsten Pietsch, Johannes EA Wolff, Rolf D Kortmann, Joachim Kuehl
发表日期
2005/3/10
期刊
New England Journal of Medicine
卷号
352
期号
10
页码范围
978-986
出版商
Massachusetts Medical Society
简介
Background
The prognosis for young children with medulloblastoma is poor, and survivors are at high risk for cognitive deficits. We conducted a trial of the treatment of this brain tumor by intensive postoperative chemotherapy alone.
Methods
After surgery, children received three cycles of intravenous chemotherapy (cyclophosphamide, vincristine, methotrexate, carboplatin, and etoposide) and intraventricular methotrexate. Treatment was terminated if a complete remission was achieved. Leukoencephalopathy and cognitive deficits were evaluated.
Results
Forty-three children were treated according to protocol. In children who had complete resection (17 patients), residual tumor (14), and macroscopic metastases (12), the five-year progression-free and overall survival rates (±SE) were 82±9 percent and 93±6 percent, 50±13 percent and 56±14 percent, and 33±14 percent and 38±15 percent, respectively. The …
引用总数
200520062007200820092010201120122013201420152016201720182019202020212022202320241332484742547856534150333753374544313818
学术搜索中的文章
S Rutkowski, U Bode, F Deinlein, H Ottensmeier… - New England Journal of Medicine, 2005